UA124616C2 - Зв'язуюче тау-білок антитіло - Google Patents

Зв'язуюче тау-білок антитіло Download PDF

Info

Publication number
UA124616C2
UA124616C2 UAA201711739A UAA201711739A UA124616C2 UA 124616 C2 UA124616 C2 UA 124616C2 UA A201711739 A UAA201711739 A UA A201711739A UA A201711739 A UAA201711739 A UA A201711739A UA 124616 C2 UA124616 C2 UA 124616C2
Authority
UA
Ukraine
Prior art keywords
tau
antibody
binding
binding fragment
rgo
Prior art date
Application number
UAA201711739A
Other languages
English (en)
Ukrainian (uk)
Inventor
Девід Едвард Ормонде Найт
Дэвид Эдвард Ормонде Найт
Теренц Сьюард Бейкер
Девід Джеймс МакМіллан
Дэвид Джеймс МакМиллан
Роберт Ентоні Гріффін
Роберт Энтони ГРИФФИН
Жорж Маірет-Коельо
Жорж Маирет-Коэльо
Патрік Дауні
Патрик Дауни
Жан-Філіпп Коурад
Жан-Филипп Коурад
Original Assignee
Юсб Біофарма Срл
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA124616(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсб Біофарма Срл, Юсб Биофарма Срл filed Critical Юсб Біофарма Срл
Publication of UA124616C2 publication Critical patent/UA124616C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
UAA201711739A 2015-07-06 2016-07-05 Зв'язуюче тау-білок антитіло UA124616C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
PCT/EP2016/065813 WO2017005734A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (1)

Publication Number Publication Date
UA124616C2 true UA124616C2 (uk) 2021-10-20

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201711739A UA124616C2 (uk) 2015-07-06 2016-07-05 Зв'язуюче тау-білок антитіло

Country Status (25)

Country Link
US (4) US10287343B2 (OSRAM)
EP (1) EP3319983A1 (OSRAM)
JP (3) JP6630426B2 (OSRAM)
KR (2) KR20250027278A (OSRAM)
CN (1) CN107849104B (OSRAM)
AR (1) AR105267A1 (OSRAM)
AU (1) AU2016289755C1 (OSRAM)
CA (1) CA2991451A1 (OSRAM)
CL (1) CL2018000043A1 (OSRAM)
CO (1) CO2017012971A2 (OSRAM)
EA (1) EA037092B1 (OSRAM)
EC (1) ECSP18000887A (OSRAM)
IL (1) IL256685B (OSRAM)
MA (2) MA41670A1 (OSRAM)
MX (1) MX2017015817A (OSRAM)
MY (1) MY193677A (OSRAM)
PE (1) PE20180481A1 (OSRAM)
PH (1) PH12017502207B1 (OSRAM)
SG (1) SG10202010735PA (OSRAM)
TN (1) TN2017000539A1 (OSRAM)
TW (1) TWI745295B (OSRAM)
UA (1) UA124616C2 (OSRAM)
UY (1) UY36773A (OSRAM)
WO (1) WO2017005734A1 (OSRAM)
ZA (1) ZA201800027B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3303386T3 (pl) 2015-06-05 2025-03-03 Genentech, Inc. Przeciwciała anty-tau i sposoby zastosowania
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
TWI787219B (zh) 2016-12-07 2022-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
CA3147548A1 (en) * 2019-08-13 2021-02-18 Randall Bateman Methods to detect mtbr tau isoforms and use thereof
WO2021163031A1 (en) 2020-02-12 2021-08-19 Eli Lilly And Company Crystallization of antibodies or antigen-binding fragments
WO2021262791A1 (en) 2020-06-25 2021-12-30 Merck Sharp & Dohme Corp. High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2024107745A1 (en) * 2022-11-14 2024-05-23 Washington University Methods to detect csf mtbr-tau and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010063123A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
AU2010305284A1 (en) 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
RU2603078C2 (ru) 2010-10-07 2016-11-20 Ац Иммуне С.А. Фармацевтическая композиция
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
BR112014006376B1 (pt) 2011-09-19 2021-07-27 Axon Neuroscience Se Anticorpo isolado que se liga a um ou mais epítopos tau, ácido nucleico, vetor, composição farmacêutica, artigo de fabricação, dispositivo médico, método in vitro para diagnosticar ou triar um indivíduo quanto à presença de doença de alzheimer ou de uma tauopatia relacionada e usos do referido anticorpo
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
NZ626269A (en) * 2011-12-20 2016-06-24 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
EP3838921A3 (en) 2012-07-03 2021-09-01 Washington University Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies

Also Published As

Publication number Publication date
AU2016289755C1 (en) 2021-08-19
CL2018000043A1 (es) 2018-05-18
HK1246804A1 (zh) 2018-09-14
CN107849104A (zh) 2018-03-27
SG10202010735PA (en) 2020-11-27
US20230416350A1 (en) 2023-12-28
IL256685A (en) 2018-03-29
AU2016289755B2 (en) 2020-12-03
AU2016289755A1 (en) 2018-01-04
US10287343B2 (en) 2019-05-14
ZA201800027B (en) 2019-06-26
PH12017502207A1 (en) 2018-06-11
JP2018524001A (ja) 2018-08-30
WO2017005734A1 (en) 2017-01-12
US20190284267A1 (en) 2019-09-19
PE20180481A1 (es) 2018-03-07
JP7413448B2 (ja) 2024-01-15
MA42377A (fr) 2018-05-16
CA2991451A1 (en) 2017-01-12
BR112017028102A2 (en) 2018-09-04
TWI745295B (zh) 2021-11-11
CO2017012971A2 (es) 2018-03-09
US20210115121A1 (en) 2021-04-22
US10889640B2 (en) 2021-01-12
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
CN107849104B (zh) 2021-08-27
EA037092B1 (ru) 2021-02-04
KR20250027278A (ko) 2025-02-25
JP7100008B2 (ja) 2022-07-12
EP3319983A1 (en) 2018-05-16
ECSP18000887A (es) 2018-03-31
MX2017015817A (es) 2018-04-10
MY193677A (en) 2022-10-25
TW201713689A (zh) 2017-04-16
IL256685B (en) 2022-02-01
AR105267A1 (es) 2017-09-20
JP2022141689A (ja) 2022-09-29
MA41670A1 (fr) 2018-05-31
US11732034B2 (en) 2023-08-22
EA201890172A1 (ru) 2018-10-31
JP6630426B2 (ja) 2020-01-15
NZ738058A (en) 2021-07-30
UY36773A (es) 2017-01-31
US20180201666A1 (en) 2018-07-19
JP2020055849A (ja) 2020-04-09
KR102770650B1 (ko) 2025-02-19
PH12017502207B1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
UA124616C2 (uk) Зв'язуюче тау-білок антитіло
TWI705975B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
JP7016470B2 (ja) 抗トランスサイレチン抗体
CN111315774B (zh) 抗fam19a5抗体及其用途
US7906120B2 (en) Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)
US20170298138A1 (en) Cell senescence markers as diagnostic and therapeutic targets
UA118749C2 (uk) Конструкція антитіла до cdh19 і cd3
JP7750745B2 (ja) ＡｐｏＥ抗体、融合タンパク質、およびその使用
TW201713688A (zh) Ｔａｕ結合抗體
CA2163344A1 (en) Humanised antibodies
JP2017509594A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
UA124622C2 (uk) Кон'юговані імуноглобуліни з c-кінцевим лізином
CN109071675A (zh) 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
JP7052059B2 (ja) ヒト原形質膜小胞関連蛋白質ｐｖ－１と特異的に結合するモノクローナル抗体およびその製造方法と使用
PT1720909E (pt) Anticorpo anti-a¿ò
CN109988240B (zh) 抗gpc-3抗体及其用途
JP2022514290A (ja) 改変抗体ｆｃおよび使用方法
CN110028584A (zh) 针对egfr蛋白和met蛋白的双特异性抗体
CN119161481A (zh) 用于治疗的药剂、用途和方法
US8512704B2 (en) Tmem27 antibody
EP4537841A1 (en) Pharmaceutical composition containing anti-integrin alpha-11 antibody for treatment or prevention of aging-related diseases
KR20220143786A (ko) 중추 신경계 질환을 치료하기 위한 항-fam19a1 길항제의 용도
CN120603851A (zh) 用于治疗神经退行性疾病的人抗trem2抗体
CN121057743A (zh) 糖基化多肽
BR122024024316A2 (pt) Métodos para produzir uma seringa pré-cheia, para preparação de uma seringa pré-cheia compreendendo aflibercepte e para preparação de uma seringa autoinjetora pré-cheia compreendendo aflibercepte